PMID- 28905041
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 2451-0629 (Print)
IS  - 2451-0629 (Electronic)
IS  - 2451-0629 (Linking)
VI  - 2
IP  - 1
DP  - 2017
TI  - Presepsin (sCD14-ST): could it be a novel marker for the diagnosis of ST 
      elevation myocardial infarction?
PG  - e3-e8
LID - 10.5114/amsad.2017.66827 [doi]
AB  - INTRODUCTION: Acute myocardial infarction (AMI) could be considered to be a state 
      of inflammation. Many inflammatory markers have been evaluated in the AMI setting 
      so far. Presepsin (PSP) is a novel biomarker for diagnosis and prognosis of 
      systemic inflammation that has not been studied in the AMI setting to date. In 
      this study, we aimed to examine serum PSP levels in patients with acute ST 
      elevation myocardial infarction (STEMI). MATERIAL AND METHODS: Forty-eight 
      patients with STEMI and fifty healthy controls without coronary artery disease, 
      verified by coronary angiography, were included in the study. Together with 
      routine laboratory tests needed for STEMI, plasma concentrations of PSP were 
      measured in peripheral venous blood samples of the participants. RESULTS: Plasma 
      PSP and troponin levels were significantly higher in patients with STEMI than 
      controls (1988.89 +/-3101.55 vs. 914.22 +/-911.35 pg/ml, p = 0.001 and 3.46 +/-3.39 vs. 
      0.08 +/-0.43 ng/ml, p = 0.001, respectively). The cut-off value for PSP of 447 
      pg/ml was found to detect STEMI with 87.5% sensitivity, 44% specificity, 60% 
      positive predictive value and 78.5% negative predictive value. CONCLUSIONS: In 
      this study, PSP levels were found to be significantly elevated in patients with 
      STEMI together with high-sensitivity troponins. The PSP may be a new marker for 
      AMI detection. Large scale studies are needed to reveal the importance of PSP in 
      the diagnosis and prognosis of AMI.
FAU - Caglar, Fatma Nihan Turhan
AU  - Caglar FNT
AD  - Department of Cardiology, Bakirkoy Dr. Sadi Konuk Education and Research 
      Hospital, Istanbul, Turkey.
FAU - Isiksacan, Nilgun
AU  - Isiksacan N
AD  - Department of Biochemistry, Bakirkoy Dr. Sadi Konuk Education and Research 
      Hospital, Istanbul, Turkey.
FAU - Biyik, Ismail
AU  - Biyik I
AD  - Department of Cardiology, Usak University Education and Research Hospital, Usak, 
      Turkey.
FAU - Opan, Selcuk
AU  - Opan S
AD  - Department of Cardiology, Bakirkoy Dr. Sadi Konuk Education and Research 
      Hospital, Istanbul, Turkey.
FAU - Cebe, Hulya
AU  - Cebe H
AD  - Department of Cardiology, Bakirkoy Dr. Sadi Konuk Education and Research 
      Hospital, Istanbul, Turkey.
FAU - Akturk, Ibrahim Faruk
AU  - Akturk IF
AD  - Department of Cardiology, Bakirkoy Dr. Sadi Konuk Education and Research 
      Hospital, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20170327
PL  - Poland
TA  - Arch Med Sci Atheroscler Dis
JT  - Archives of medical sciences. Atherosclerotic diseases
JID - 101701205
PMC - PMC5596112
OTO - NOTNLM
OT  - atherosclerosis
OT  - inflammation
OT  - myocardial infarction
OT  - presepsin
EDAT- 2017/09/15 06:00
MHDA- 2017/09/15 06:01
PMCR- 2017/03/27
CRDT- 2017/09/15 06:00
PHST- 2017/03/03 00:00 [received]
PHST- 2017/03/12 00:00 [accepted]
PHST- 2017/09/15 06:00 [entrez]
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2017/09/15 06:01 [medline]
PHST- 2017/03/27 00:00 [pmc-release]
AID - 29698 [pii]
AID - 10.5114/amsad.2017.66827 [doi]
PST - epublish
SO  - Arch Med Sci Atheroscler Dis. 2017 Mar 27;2(1):e3-e8. doi: 
      10.5114/amsad.2017.66827. eCollection 2017.